Linked breast and ovarian cancer susceptibility gene
Patent 5709999 Issued on January 20, 1998. Estimated Expiration Date: June 7, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
435/6, Involving nucleic acid435/91.2, Acellular exponential or geometric amplification (e.g., PCR, etc.)536/23.1, DNA or RNA fragments or modified forms thereof (e.g., genes, etc.)536/24.3, Probes for detection of specific nucleotide sequences or primers for the synthesis of DNA or RNA536/24.33Primers
The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA1 gene for mutations, which are useful for diagnosing the predisposition to breast and ovarian cancer.
Other References
Albertsen, H., et al. (1994). "Genetic Mapping of the BRCA1 Region on Chromosome 17q21," Am. J. Hum. Genet. 54:516-525
Anderson, D.E. (1972). "A Genetic Study of Human Breast Cancer," J. Natl. Cancer Inst. 48:1029-1034
Arason, A., et al. (1993). "Linkage Analysis of Chromosome 17q Markers and Breast-Ovarian Cancer in Icelandic Families, and Possible Relationship to Prostatic Cancer," Am. J. Hum. Genet. 52:711-717
Bishop, T.D. and Gardner, E.J. (1980). "Analysis of the Genetic Predisposition to Cancer in Individual Pedigrees," Banbury Report 4: Cancer Incidence in Defined Populations, Cairns et al., eds., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, pp. 389-408
Bishop, D.T., et al. (1988). "Segregation and Linkage Analysis of Nine Utah Breast Cancer Pedigrees," Genet. Epidemiol. 5:151-169
Black, D.M., et al. (1993). "A Somatic Cell Hybrid Map of the Long Arm of Human Chromosome 17, Containing the Familial Breast Cancer Locus (BRCA1)," Am. J. Hum. Genet. 52:702-710
Bowcock, A.M., et al. (1993). "THRA1 and D17S183 Flank an Interval of <4cM for the Breast-Ovarian Cancer Gene (BRCA1) on Chromosome 17q21," Am. J. Hum. Genet. 52:718-722
Boyd, J. (1995). "BRCA1: More than a hereditary breast cancer gene?" Nature Genetics 9:335-336
Chamberlain, J.S., et al. (1993). "BRCA1 Maps Proximal to D17S579 on Chromosome 17q21 by Genetic Analysis," Am. J. Hum. Genet. 52:792-798
Claus, E.B., et al. (1991). "Genetic Analysis of Breast Cancer in the Cancer and Steroid Hormone Study," Am. J. Hum. Genet. 48:232-242
Cohen, B.B., et al. (1993). "Linkage of a Major Breast Cancer Gene to Chromosome 17q12-21: Results from 15 Edinburgh Families," Am. J. Hum. Genet. 52:723-729
Devilee, P., et al. (1993). "Linkage to Markers for the Chromosome Region 17q12-q21 in 13 Dutch Breast Cancer Kindreds," Am. J. Hum. Genet. 52:730-735
Dunphy, W.G. and Newport, J.W. (1989). "Fission Yeast p13 Blocks Mitotic Activation and Tyrosine Dephosphorylation of the Xenopus cdc2 Protein Kinase," Cell 58:181-191
Easton, D.F., et al. (1993). "Genetic Linkage Analysis in Familial Breast and Ovarian Cancer: Results from 214 Families," Am. J. Hum. Genet. 52:678-701
Fain, P.R. (1992). "Third International workshop on human chromosome 17 mapping," Cytogen. Cell Genet. 60:178-186
Feunteun, J., et al. (1993). "A Breast-Ovarian Cancer Susceptibility Gene Maps to Chromosome 17q21," Am. J. Hum. Genet. 52:736-742
Ford, D., et al. (1993). "The risks of cancer in BRCA1 mutation carriers," Am. J. Hum. Genet. 53(supplement):abstract No. 298
Futreal, P.A., et al. (1994). "BRCA1 Mutations in Primary Breast and Ovarian Carcinomas," Science 266:120-122
Go, R.C.P., et al. (1983). "Genetic Epidemiology of Breast Cancer and Associated Cancers in High-Risk Families. I. Segregation Analysis," J. Natl. Cancer Inst. 71:455-461
Goldgar, D.E., et al. (1993). "Chromosome 17q Linkage Studies of 18 Utah Breast Cancer Kindreds," Am. J. Hum. Genet. 52:743-748
Gould, K.L. and Nurse, P. (1989). "Tyrosine phosphorylation of the fission yeast cdc2+ protein kinase regulates entry into mitosis," Nature 342:39-45
Hall, J.M., et al. (1990). "Linkage of Early-Onset Familial Breast Cancer to Chromosome 17q21," Science 250:1684-1689
Hall, J.M., et al. (1992). "Closing in on a Breast Cancer Gene on Chromosome 17q," Am. J. Hum. Genet. 50:1235-1241
Hosking, K., et al. (1995). "A somatic BRCA1 mutation in an ovarian tumour," Nature Genetics 9:343-344
Ishibashi, T., et al. (1992). "Expression cloning of a human dual-specificity phosphatase," Proc. Natl. Acad. Sci USA 89:12170-12174
Kamb, A., et al. (1994). "Localization of the VHR Phosphatase Gene and Its Analysis as a Candidate for BRCA1," Genomics 23:163-167
Kumagai, A. and Dunphy, W.G. (1991). "The cdc25 Protein Controls Tyrosine Dephosphorylation of the cdc2 Protein in a Cell-Free System," Cell 64:903-914
Lindblom, A., et al. (1993). "Linkage Analysis with Markers on 17q in 29 Swedish Breast Cancer Families," Am. J. Hum. Genet. 52:749-753
Malkin, D., et al. (1990). "Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms," Science 250:1233-1238
Margaritte, P., et al. (1992). "Linkage of Familial Breast Cancer to Chromosome 17q21 May Not be Restricted to Early-Onset Disease," Am. J. Hum. Genet. 50:1231-1234
Mazoyer, S., et al. (1993). "Linkage Analysis of 19 French Breast Cancer Families, with Five Chromosome 17q Markers," Am. J. Hum. Genet. 52:754-760
Merajver, S.D., et al. (1995). "Somatic mutations in the BRCA1 gene in sporadic ovarian tumours," Nature Genetics 9:439-443
Miki, Y., et al. (1994). "A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1," Science 266:66-71
Milner, B.J., et al. (1993). "Linkage Studies with 17q and 18q Markers in a Breast/Ovarian Cancer Family," Am. J. Hum. Genet. 52:761-766
Narod, S.A., et al. (1991). "Familial breast-ovarian cancer locus on chromosome 17q12-q23," Lancet 338:82-83
Newman, B. et al. (1988). "Inheritance of human breast cancer: Evidence for autosomal dominant transmission in high-risk families," Proc. Natl. Acad. Sci. USA 85:3044-3048
O'Connell, P., et al. (1994). "A Radiation Hybrid Map of the BRCA1 Region," Am. J. Hum. Genet. 54:526-534
Roberts, L. (1993). "Zeroing In on a Breast Cancer Susceptibility Gene," Science 259:622-625
Shattuck-Eidens, D., et al. (1995). "A Collaborative Survey of 80 Mutations in the BRCA1 Breast and Ovarian Cancer Susceptibility Gene," JAMA 273:535-541
Simard, J., et al. (1994). "Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families," Nature Genetics 8:392-398
Smith, S.A., et al. (1992). "Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome," Nature Genetics 2:128-131
Smith, S.A., et al. (1993). "Genetic Heterogeneity and Localization of a Familial Breast-Ovarian Cancer Gene on Chromosome 17q12-q21," Am. J. Hum. Genet. 52:767-776
Spurr, N.K., et al. (1993). "Linkage Analysis of Early-Onset Breast and Ovarian Cancer Families, with Markers on the Long Arm of Chromosome 17," Am. J. Hum. Genet. 52:777-785
Teare, M.D., et al. (1993). "A Linkage Study in Seven Breast Cancer Families," Am. J. Hum. Genet. 52: 786-788
Thompson, M.E., et al. (1995). "Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression," Nature Genetics 9:444-450
Ullrich, A. and Schlessinger, J. (1990). "Signal Transductin by Receptors with Tyrosine Kinase Activity," Cell 61:203-212
Castilla et al. Nature Genetics 8: 387-391, 1994
Friedman et al. Nature Genetics 8: 1-6, 1994
Castilla, L. H. et al. (1994). "Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer," Nature Genetics 8:87-391
Friedman, L.S. et al. (1994). "Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families," Nature Genetics 8:399-404
Goldgar, D.E. et al. (1994). "A Large Kindred With 17q-Linked Breast and Ovarian Cancer: Genetic, Phenotypic, and Genealogical Analysis," J. Natl. Caner Institute 86:200-209
Liang, P. et al. (1992). "Differential Display and Cloning of Messenger RNAs from Human Breast Cancer versus Mammary Epithelial Cells," Cancer Research 52:6966-6968
Neuhausen, S.L. et al. (1994). "A Pl-based physical map of the region from D17S776 to D17378 containing the breast cancer susceptibility gene BRCA1," Hum. Mol. Gen. 3:1919-1926
Sato, T. et al. (1992). "The Human Prohibition Gene Located on Chromosome 17q21 is Mutated in Sporadic Breast Cancer," Cancer Research 52:1543-1646
Stampfer, M.R. et al. (1993). "Culture Systems for Study of Human Mammary Epithelial Cell Proliferation, Differentiation and Transformation," Cancer Surveys 18:7-34
Wooster, R. et al. (1994). "Localization of a Breast Cancer Susceptibility Gene, BRCA2, to Chromosome 13q12-13," Science 265:2088-2090
Williams, W.R. and Anderson, D.E. (1984). "Genetic Epidemiology of Breast Cancer: Segregation Analysis of 200 Danish Pedigrees," Genet. Epidemiol. 1:7-20
Zimmermann, W., et al. (1993). "Linkage Analysis in German Breast Cancer Families with Early Onset of the Disease, Using Highly Polymorphic Markers from the Chromosome 17q11-q24 Region," Am. J. Hum. Genet. 52:789-79
June 7, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
